

NOVO NORDISK A S  
Form 6-K  
January 06, 2017

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER**

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

January 3, 2017

---

**NOVO NORDISK A/S**

(Exact name of Registrant as specified in its charter)

**Novo Allé**

**DK- 2880, Bagsvaerd**

**Denmark**

(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-\_\_\_\_\_

**Novo Nordisk A/S - Status regarding Novo Nordisk's holding of its own shares (31 December 2016)**

**Bagsværd, Denmark, 2 January 2017** - In continuation of the company's announcements dated 5 August 2016 and 28 October 2016 concerning planned share repurchase programmes, and pursuant to Section 204.25 of the New York Stock Exchange Listed Company Manual, this is to report that Novo Nordisk A/S (NYSE: NVO) and its wholly-owned affiliates on 31 December 2016 owned 45,667,252 of its own B shares of DKK 0.20, corresponding to a total nominal value of DKK 9,133,450 or 1.8% of the total share capital.

In the fourth quarter of 2016 a total of 16,190,604 B shares were repurchased, and zero B shares were disposed to employees in connection with employee incentive programmes.

## Edgar Filing: NOVO NORDISK A S - Form 6-K

*Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,300 people in 75 countries and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](http://novonordisk.com), Facebook, Twitter, LinkedIn, YouTube*

### Further information

#### Media:

Anne Margrethe Hauge +45 4442 3450 amhg@novonordisk.com  
Ken Inchausti (US) +1 609 786 8316 kiau@novonordisk.com

#### Investors:

Peter Hugrefte Ankersen +45 3075 9085 phak@novonordisk.com  
Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com  
Hanna Ögren +45 3079 8519 haoe@novonordisk.com  
Anders Mikkelsen +45 3079 4461 armk@novonordisk.com  
Kasper Veje (US) +1 609 235 8567 kpvj@novonordisk.com

		Telephone:	Internet:
<b>Novo Nordisk A/S</b>	Novo Allé	+45 4444 8888	<a href="http://www.novonordisk.com">www.novonordisk.com</a>
Investor Relations	2880 Bagsværd	Telefax:	CVR no:
	Denmark	+45 4444 6626	24 25 67 90
		Company announcement No 1 / 2017	

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

NOVO NORDISK A/S

Date: January 3, 2017

Lars Rebien Sørensen.

Chief Executive Officer